PH12018501276A1 - Water-soluble derivatives of 3,5-diphenyl-diazole compounds - Google Patents
Water-soluble derivatives of 3,5-diphenyl-diazole compoundsInfo
- Publication number
- PH12018501276A1 PH12018501276A1 PH12018501276A PH12018501276A PH12018501276A1 PH 12018501276 A1 PH12018501276 A1 PH 12018501276A1 PH 12018501276 A PH12018501276 A PH 12018501276A PH 12018501276 A PH12018501276 A PH 12018501276A PH 12018501276 A1 PH12018501276 A1 PH 12018501276A1
- Authority
- PH
- Philippines
- Prior art keywords
- diphenyl
- derivatives
- disease
- diazole
- water
- Prior art date
Links
- JXHKUYQCEJILEI-UHFFFAOYSA-N 3,5-diphenyl-1h-pyrazole Chemical class C=1C(C=2C=CC=CC=2)=NNC=1C1=CC=CC=C1 JXHKUYQCEJILEI-UHFFFAOYSA-N 0.000 title abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 208000024777 Prion disease Diseases 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 2
- 230000004845 protein aggregation Effects 0.000 abstract 2
- 102100034452 Alternative prion protein Human genes 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
- C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15199972 | 2015-12-14 | ||
| PCT/EP2016/081084 WO2017102893A1 (en) | 2015-12-14 | 2016-12-14 | Water-soluble derivatives of 3,5-diphenyl-diazole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12018501276A1 true PH12018501276A1 (en) | 2019-01-28 |
Family
ID=54850017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12018501276A PH12018501276A1 (en) | 2015-12-14 | 2018-06-14 | Water-soluble derivatives of 3,5-diphenyl-diazole compounds |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10308671B2 (enExample) |
| EP (1) | EP3390412B1 (enExample) |
| JP (1) | JP6898931B2 (enExample) |
| KR (1) | KR102671166B1 (enExample) |
| CN (1) | CN108473516B (enExample) |
| AU (1) | AU2016372408B2 (enExample) |
| BR (1) | BR112018011994B1 (enExample) |
| CA (1) | CA3008334C (enExample) |
| CL (1) | CL2018001570A1 (enExample) |
| DK (1) | DK3390412T3 (enExample) |
| ES (1) | ES2873510T3 (enExample) |
| HU (1) | HUE054815T2 (enExample) |
| IL (1) | IL260011B (enExample) |
| MX (1) | MX379522B (enExample) |
| NZ (1) | NZ742979A (enExample) |
| PH (1) | PH12018501276A1 (enExample) |
| PL (1) | PL3390412T3 (enExample) |
| PT (1) | PT3390412T (enExample) |
| RU (1) | RU2764131C2 (enExample) |
| WO (1) | WO2017102893A1 (enExample) |
| ZA (1) | ZA201803865B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH713150A2 (fr) * | 2016-11-23 | 2018-05-31 | Eta Sa Mft Horlogere Suisse | Mécanisme régulateur à résonateur rotatif à guidage flexible entretenu par un échappement libre à ancre. |
| US10368502B2 (en) | 2017-09-25 | 2019-08-06 | Multiple Energy Technologies Llc | Bioceramic and carbon-based hydroponic systems, methods and devices |
| EP4368184A3 (en) | 2019-11-19 | 2024-07-31 | Modag GmbH | Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein |
| US20250161273A1 (en) * | 2022-03-01 | 2025-05-22 | Modag Gmbh | Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use |
| CN115337301A (zh) * | 2022-07-22 | 2022-11-15 | 汕头大学医学院第一附属医院 | Anle138b在制备改善饮食诱导胰岛素抵抗药物中的应用 |
| CN116399983B (zh) * | 2023-06-09 | 2023-08-15 | 天津辰欣药物研究有限公司 | 一种利用gc-ms法检测二叔丁基氯甲基磷酸酯残留量的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745625B2 (en) * | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| NZ564326A (en) * | 2005-06-16 | 2010-01-29 | Cv Therapeutics Inc | Prodrugs of A2B adenosine receptor antagonists |
| EP2272822A4 (en) * | 2008-03-31 | 2012-01-18 | Renascience Co Ltd | PLASMINOG ACTIVATOR-1 HEMMER |
| EP2687513B1 (en) * | 2008-06-09 | 2020-12-02 | Ludwig-Maximilians-Universität München | Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases |
| JP6069661B2 (ja) * | 2010-06-24 | 2017-02-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用 |
| SMT201700306T1 (it) * | 2012-06-08 | 2017-07-18 | Theravance Biopharma R&D Ip Llc | Inibitori di neprilisina |
-
2016
- 2016-12-14 KR KR1020187020192A patent/KR102671166B1/ko active Active
- 2016-12-14 EP EP16809425.8A patent/EP3390412B1/en active Active
- 2016-12-14 CA CA3008334A patent/CA3008334C/en active Active
- 2016-12-14 BR BR112018011994-6A patent/BR112018011994B1/pt active IP Right Grant
- 2016-12-14 ES ES16809425T patent/ES2873510T3/es active Active
- 2016-12-14 HU HUE16809425A patent/HUE054815T2/hu unknown
- 2016-12-14 WO PCT/EP2016/081084 patent/WO2017102893A1/en not_active Ceased
- 2016-12-14 RU RU2018125590A patent/RU2764131C2/ru active
- 2016-12-14 MX MX2018006877A patent/MX379522B/es unknown
- 2016-12-14 CN CN201680073089.1A patent/CN108473516B/zh active Active
- 2016-12-14 DK DK16809425.8T patent/DK3390412T3/da active
- 2016-12-14 US US16/062,258 patent/US10308671B2/en active Active
- 2016-12-14 JP JP2018532323A patent/JP6898931B2/ja active Active
- 2016-12-14 PL PL16809425T patent/PL3390412T3/pl unknown
- 2016-12-14 AU AU2016372408A patent/AU2016372408B2/en active Active
- 2016-12-14 NZ NZ742979A patent/NZ742979A/en unknown
- 2016-12-14 PT PT168094258T patent/PT3390412T/pt unknown
-
2018
- 2018-06-11 ZA ZA2018/03865A patent/ZA201803865B/en unknown
- 2018-06-13 IL IL260011A patent/IL260011B/en unknown
- 2018-06-13 CL CL2018001570A patent/CL2018001570A1/es unknown
- 2018-06-14 PH PH12018501276A patent/PH12018501276A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN108473516B (zh) | 2021-06-18 |
| RU2018125590A (ru) | 2020-01-20 |
| CA3008334C (en) | 2024-01-02 |
| ZA201803865B (en) | 2019-04-24 |
| DK3390412T3 (da) | 2021-06-21 |
| RU2764131C2 (ru) | 2022-01-13 |
| KR20180089511A (ko) | 2018-08-08 |
| PL3390412T3 (pl) | 2021-10-25 |
| CA3008334A1 (en) | 2017-06-22 |
| ES2873510T3 (es) | 2021-11-03 |
| IL260011B (en) | 2021-12-01 |
| PT3390412T (pt) | 2021-06-22 |
| US20180370997A1 (en) | 2018-12-27 |
| MX2018006877A (es) | 2018-09-18 |
| IL260011A (en) | 2018-07-31 |
| CL2018001570A1 (es) | 2018-12-28 |
| JP2019501167A (ja) | 2019-01-17 |
| EP3390412B1 (en) | 2021-04-14 |
| MX379522B (es) | 2025-03-10 |
| WO2017102893A1 (en) | 2017-06-22 |
| KR102671166B1 (ko) | 2024-05-31 |
| CN108473516A (zh) | 2018-08-31 |
| RU2018125590A3 (enExample) | 2020-04-21 |
| AU2016372408A1 (en) | 2018-06-21 |
| NZ742979A (en) | 2022-05-27 |
| US10308671B2 (en) | 2019-06-04 |
| JP6898931B2 (ja) | 2021-07-07 |
| BR112018011994A2 (pt) | 2018-12-04 |
| BR112018011994B1 (pt) | 2022-07-19 |
| EP3390412A1 (en) | 2018-10-24 |
| HUE054815T2 (hu) | 2021-10-28 |
| AU2016372408B2 (en) | 2021-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501276A1 (en) | Water-soluble derivatives of 3,5-diphenyl-diazole compounds | |
| PH12015501942A1 (en) | Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders | |
| PH12018500087A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
| SA518400660B1 (ar) | مركبات بيرميدين-2-يل أمينو -1h- بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبيةlrrk2 | |
| EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
| MX386258B (es) | Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas | |
| EA201890307A1 (ru) | Индазольные и азаиндазольные соединения как ингибиторы irak-4 | |
| MX378707B (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
| WO2015108490A3 (en) | Heteroaryl alkyne derivatives and uses thereof | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| IN2014KN00929A (enExample) | ||
| NZ727358A (en) | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof | |
| EA201270480A1 (ru) | Новые соединения | |
| EA201391485A1 (ru) | Способы и композиции для лечения нейродегенеративных заболеваний | |
| PH12017500841A1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
| MX369952B (es) | Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de transcripción de choque térmico 1. | |
| MX378266B (es) | Inhibidores de gingipaina de lisina. | |
| MX394882B (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta) | |
| MX2024013291A (es) | Metodos para tratar trastornos neurodegenerativos | |
| TN2015000275A1 (fr) | 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease | |
| HK1198514A1 (en) | Substituted heterocyclic compounds for disease treatment | |
| SG11202004940VA (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
| WO2017103892A3 (en) | Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease |